Centocor joins its parent company in blogosphere

Share this article:

Centocor launched itself into the blogosphere with the debut of its corporate blog at cnto411.com.

Melissa Katz, a Centoco spokeswoman, told MM&M the corporate blog aims to serve as a forum for discussion on issues relevant to the industry and not a platform for sounding off on Centocor products.

“I plan on posting to the blog as often as I can on issues that are relevant, hopefully a couple of times a week,” Katz said.

Michael Parks, VP of corporate comms and executive producer of Centocor's unbranded feature length film Innerstate, will serve in the role the blog's guest author.

“Around the time of Innerstate's debut about a year ago, we realized that we weren't paying enough attention to the blogosphere,” Katz said. “Since then we have been working with those bloggers to see how we can better communicate with them.”

Centocor joins its parent company Johnson & Johnson, which began corporate blogging with jnjbtw.com last summer.

Johnson & Johnson's blog, edited by spokesman Marc Monseau, has taken a similar tack as a forum for discussion of non-product specific, industry-related issues.

On the product blogging front, GlaxoSmithKline's Alli team keeps a blog on the OTC weight loss treatment (alliconnect.com).

Novartis briefly experimented with an oncology blog, melanomaperspectives.com, aimed at physicians and written by KOLs, toward the end of 2007, but quickly pulled it.

 

 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?